Neurotech International has received Human Research Ethics Committee (HREC) approval to extend a Phase I/II clinical trial of its NTI164 cannabinoid drug candidate in autism spectrum disorder (ASD) by another 52 weeks.
The extension was based on requests from the trial’s lead investigator Professor Michael Fahey as well as from patients and their caregivers.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Vel turpis nunc eget lorem dolor sed. Sit amet consectetur adipiscing elit duis tristique sollicitudin nibh. Nisl nunc mi ipsum faucibus vitae.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
